LIVINGSTON, N.J.--(BUSINESS WIRE)--March 7, 2006--Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced financial results for the fourth quarter and year ended December 31, 2005. Highlights of fiscal 2005 included:
-- Revenues increased 23% to $22.0 million from $17.9 million in 2004; -- Operating expenses decreased 34% to $21.2 million from $32 million in 2004; -- Net loss improved 63% to $9.3 million from a net loss of $25.1 million in 2004; -- Net loss per share improved to $0.23 per share versus a net loss of $0.62 per share in 2004; -- The European patent office granted a patent for the use of carbamide peroxide in Columbia's bioadhesive delivery system for the treatment of bacterial vaginosis; -- The IND for a new Phase II study of vaginally-administered lidocaine for the prevention and treatment of dysmenorrhea was filed with and accepted by the FDA; and, -- Enrollment in the Phase III study of Prochieve(R) 8% for the prevention of preterm birth continued to increase and passed the 400-patient mark in February 2006.
